Polymorphic forms of naltrexone
US-9221830-B2 · Dec 29, 2015 · US
Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation
US8980908B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8980908-B2 |
| Application number | US-201414287254-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 27, 2014 |
| Priority date | Jan 16, 2009 |
| Publication date | Mar 17, 2015 |
| Grant date | Mar 17, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Selective, non-peptide antagonists of the mu opioid receptor (MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding assays, and to treat conditions related to addiction in which MOR is involved, e.g. heroin, prescription drug and alcohol addiction, as well as in the treatment of opioid induced constipation (OIC).
First claim
Opening claim text (preview).
We claim: 1. A selective, non-peptide MOR antagonist of the general formula wherein the MOR antagonist may be a racemic mixture or a purified racemate; the nitrogen (N) at the 17N position may be charged and substituted with a C1-10 aryl or alkaryl, or may be uncharged and unsubstituted; Z is selected from the group consisting of a substituted or unsubstituted aliphatic mo…
Assignees
Inventors
Classifications
- C07D489/08Primary
Chemistry & Metallurgy · mapped topic
Physics · mapped topic
Physics · mapped topic
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8980908B2 cover?
- Selective, non-peptide antagonists of the mu opioid receptor (MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding assays, and to treat conditions related to addiction in which MOR is involved, e.g. heroin, prescription drug and alcohol addiction, as well as in the treatment of opioid induced constipation (OIC).
- Who is the assignee on this patent?
- Univ Virginia Commonwealth
- What technology area does this patent fall under?
- Primary CPC classification C07D489/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).